How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
35
SPRY Quote, Financials, Valuation and Earnings
Last price:
$10.03
Seasonality move
:
-5.05%
Day range:
$9.70 - $10.05
52-week range:
$6.66 - $18.90
Dividend yield:
0%
P/E ratio:
174.21x
P/S ratio:
6.91x
P/B ratio:
6.71x
Volume:
1.2M
Avg. volume:
1.6M
1-year change:
-21.64%
Market cap:
$991.5M
Revenue:
$89.1M
EPS (TTM):
-$0.81
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SPRY
ARS Pharmaceuticals, Inc.
|
$25.6M | -$0.48 | 211.83% | -79.14% | $28.83 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.5M | $0.14 | 13.44% | 28.72% | $31.11 |
|
AGEN
Agenus, Inc.
|
$28.1M | -$1.30 | 329.24% | -36.28% | $12.33 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 110.49% | -58.59% | $479.79 |
|
SVRA
Savara, Inc.
|
-- | -$0.12 | -- | -2.6% | $10.81 |
|
VVOS
Vivos Therapeutics, Inc.
|
$7.1M | -$0.48 | 91.91% | -0.69% | $5.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SPRY
ARS Pharmaceuticals, Inc.
|
$10.03 | $28.83 | $991.5M | 174.21x | $0.00 | 0% | 6.91x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$23.56 | $31.11 | $4B | 15.16x | $0.00 | 0% | 3.79x |
|
AGEN
Agenus, Inc.
|
$2.94 | $12.33 | $100M | -- | $0.00 | 0% | 0.74x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$328.16 | $479.79 | $43.4B | 1,364.49x | $0.00 | 0% | 13.46x |
|
SVRA
Savara, Inc.
|
$5.30 | $10.81 | $1.1B | -- | $0.00 | 0% | -- |
|
VVOS
Vivos Therapeutics, Inc.
|
$1.55 | $5.00 | $13.9M | -- | $0.00 | 0% | 0.77x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SPRY
ARS Pharmaceuticals, Inc.
|
39.84% | -1.079 | 9.84% | 6.38x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.900 | 1.52% | 2.70x |
|
AGEN
Agenus, Inc.
|
510.35% | 4.019 | 285.06% | 0.03x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
92.22% | 1.064 | 4.61% | 2.37x |
|
SVRA
Savara, Inc.
|
24.02% | -1.971 | 4.83% | 7.42x |
|
VVOS
Vivos Therapeutics, Inc.
|
83.15% | 1.597 | 48.77% | 0.77x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SPRY
ARS Pharmaceuticals, Inc.
|
$24.3M | -$53.2M | -35.53% | -38.98% | -163.66% | -$47.2M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
AGEN
Agenus, Inc.
|
$26.6M | -$4.9M | -39.69% | -- | -16.08% | -$14.7M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1B | $368M | 1.51% | 31.15% | 29.46% | $313M |
|
SVRA
Savara, Inc.
|
-$76K | -$30.3M | -65.99% | -78.83% | -- | -$22.5M |
|
VVOS
Vivos Therapeutics, Inc.
|
$3.6M | -$4.7M | -153.33% | -315.1% | -69.79% | -$4.1M |
ARS Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns SPRY or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -157.38% compared to ARS Pharmaceuticals, Inc.'s net margin of 25.76%. ARS Pharmaceuticals, Inc.'s return on equity of -38.98% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital SPRYARS Pharmaceuticals, Inc.74.8% -$0.52 $245.4M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About SPRY or ACAD?
ARS Pharmaceuticals, Inc. has a consensus price target of $28.83, signalling upside risk potential of 187.47%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.11 which suggests that it could grow by 32.03%. Given that ARS Pharmaceuticals, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe ARS Pharmaceuticals, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SPRYARS Pharmaceuticals, Inc.6 0 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is SPRY or ACAD More Risky?
ARS Pharmaceuticals, Inc. has a beta of 0.787, which suggesting that the stock is 21.277% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock SPRY or ACAD?
ARS Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ARS Pharmaceuticals, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPRY or ACAD?
ARS Pharmaceuticals, Inc. quarterly revenues are $32.5M, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. ARS Pharmaceuticals, Inc.'s net income of -$51.2M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, ARS Pharmaceuticals, Inc.'s price-to-earnings ratio is 174.21x while ACADIA Pharmaceuticals, Inc.'s PE ratio is 15.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARS Pharmaceuticals, Inc. is 6.91x versus 3.79x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPRYARS Pharmaceuticals, Inc.6.91x 174.21x $32.5M -$51.2M ACADACADIA Pharmaceuticals, Inc.3.79x 15.16x $278.6M $71.8M
-
Which has Higher Returns SPRY or AGEN?
Agenus, Inc. has a net margin of -157.38% compared to ARS Pharmaceuticals, Inc.'s net margin of -116.82%. ARS Pharmaceuticals, Inc.'s return on equity of -38.98% beat Agenus, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SPRYARS Pharmaceuticals, Inc.74.8% -$0.52 $245.4M AGENAgenus, Inc.87.85% $1.94 $60.1M -
What do Analysts Say About SPRY or AGEN?
ARS Pharmaceuticals, Inc. has a consensus price target of $28.83, signalling upside risk potential of 187.47%. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 319.5%. Given that Agenus, Inc. has higher upside potential than ARS Pharmaceuticals, Inc., analysts believe Agenus, Inc. is more attractive than ARS Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SPRYARS Pharmaceuticals, Inc.6 0 0 AGENAgenus, Inc.2 1 0 -
Is SPRY or AGEN More Risky?
ARS Pharmaceuticals, Inc. has a beta of 0.787, which suggesting that the stock is 21.277% less volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.619, suggesting its more volatile than the S&P 500 by 61.86%.
-
Which is a Better Dividend Stock SPRY or AGEN?
ARS Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ARS Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPRY or AGEN?
ARS Pharmaceuticals, Inc. quarterly revenues are $32.5M, which are larger than Agenus, Inc. quarterly revenues of $30.2M. ARS Pharmaceuticals, Inc.'s net income of -$51.2M is lower than Agenus, Inc.'s net income of $63.9M. Notably, ARS Pharmaceuticals, Inc.'s price-to-earnings ratio is 174.21x while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARS Pharmaceuticals, Inc. is 6.91x versus 0.74x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPRYARS Pharmaceuticals, Inc.6.91x 174.21x $32.5M -$51.2M AGENAgenus, Inc.0.74x -- $30.2M $63.9M
-
Which has Higher Returns SPRY or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -157.38% compared to ARS Pharmaceuticals, Inc.'s net margin of 20.1%. ARS Pharmaceuticals, Inc.'s return on equity of -38.98% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15%.
Company Gross Margin Earnings Per Share Invested Capital SPRYARS Pharmaceuticals, Inc.74.8% -$0.52 $245.4M ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B -
What do Analysts Say About SPRY or ALNY?
ARS Pharmaceuticals, Inc. has a consensus price target of $28.83, signalling upside risk potential of 187.47%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $479.79 which suggests that it could grow by 46.21%. Given that ARS Pharmaceuticals, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe ARS Pharmaceuticals, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SPRYARS Pharmaceuticals, Inc.6 0 0 ALNYAlnylam Pharmaceuticals, Inc.13 8 0 -
Is SPRY or ALNY More Risky?
ARS Pharmaceuticals, Inc. has a beta of 0.787, which suggesting that the stock is 21.277% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.
-
Which is a Better Dividend Stock SPRY or ALNY?
ARS Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ARS Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPRY or ALNY?
ARS Pharmaceuticals, Inc. quarterly revenues are $32.5M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.2B. ARS Pharmaceuticals, Inc.'s net income of -$51.2M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $251.1M. Notably, ARS Pharmaceuticals, Inc.'s price-to-earnings ratio is 174.21x while Alnylam Pharmaceuticals, Inc.'s PE ratio is 1,364.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARS Pharmaceuticals, Inc. is 6.91x versus 13.46x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPRYARS Pharmaceuticals, Inc.6.91x 174.21x $32.5M -$51.2M ALNYAlnylam Pharmaceuticals, Inc.13.46x 1,364.49x $1.2B $251.1M
-
Which has Higher Returns SPRY or SVRA?
Savara, Inc. has a net margin of -157.38% compared to ARS Pharmaceuticals, Inc.'s net margin of --. ARS Pharmaceuticals, Inc.'s return on equity of -38.98% beat Savara, Inc.'s return on equity of -78.83%.
Company Gross Margin Earnings Per Share Invested Capital SPRYARS Pharmaceuticals, Inc.74.8% -$0.52 $245.4M SVRASavara, Inc.-- -$0.14 $124.2M -
What do Analysts Say About SPRY or SVRA?
ARS Pharmaceuticals, Inc. has a consensus price target of $28.83, signalling upside risk potential of 187.47%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 104.01%. Given that ARS Pharmaceuticals, Inc. has higher upside potential than Savara, Inc., analysts believe ARS Pharmaceuticals, Inc. is more attractive than Savara, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SPRYARS Pharmaceuticals, Inc.6 0 0 SVRASavara, Inc.6 0 0 -
Is SPRY or SVRA More Risky?
ARS Pharmaceuticals, Inc. has a beta of 0.787, which suggesting that the stock is 21.277% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.415%.
-
Which is a Better Dividend Stock SPRY or SVRA?
ARS Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ARS Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPRY or SVRA?
ARS Pharmaceuticals, Inc. quarterly revenues are $32.5M, which are larger than Savara, Inc. quarterly revenues of --. ARS Pharmaceuticals, Inc.'s net income of -$51.2M is lower than Savara, Inc.'s net income of -$29.6M. Notably, ARS Pharmaceuticals, Inc.'s price-to-earnings ratio is 174.21x while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARS Pharmaceuticals, Inc. is 6.91x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPRYARS Pharmaceuticals, Inc.6.91x 174.21x $32.5M -$51.2M SVRASavara, Inc.-- -- -- -$29.6M
-
Which has Higher Returns SPRY or VVOS?
Vivos Therapeutics, Inc. has a net margin of -157.38% compared to ARS Pharmaceuticals, Inc.'s net margin of -79.61%. ARS Pharmaceuticals, Inc.'s return on equity of -38.98% beat Vivos Therapeutics, Inc.'s return on equity of -315.1%.
Company Gross Margin Earnings Per Share Invested Capital SPRYARS Pharmaceuticals, Inc.74.8% -$0.52 $245.4M VVOSVivos Therapeutics, Inc.52.38% -$0.49 $15M -
What do Analysts Say About SPRY or VVOS?
ARS Pharmaceuticals, Inc. has a consensus price target of $28.83, signalling upside risk potential of 187.47%. On the other hand Vivos Therapeutics, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 222.58%. Given that Vivos Therapeutics, Inc. has higher upside potential than ARS Pharmaceuticals, Inc., analysts believe Vivos Therapeutics, Inc. is more attractive than ARS Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SPRYARS Pharmaceuticals, Inc.6 0 0 VVOSVivos Therapeutics, Inc.2 1 0 -
Is SPRY or VVOS More Risky?
ARS Pharmaceuticals, Inc. has a beta of 0.787, which suggesting that the stock is 21.277% less volatile than S&P 500. In comparison Vivos Therapeutics, Inc. has a beta of 6.931, suggesting its more volatile than the S&P 500 by 593.149%.
-
Which is a Better Dividend Stock SPRY or VVOS?
ARS Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vivos Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ARS Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Vivos Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPRY or VVOS?
ARS Pharmaceuticals, Inc. quarterly revenues are $32.5M, which are larger than Vivos Therapeutics, Inc. quarterly revenues of $6.8M. ARS Pharmaceuticals, Inc.'s net income of -$51.2M is lower than Vivos Therapeutics, Inc.'s net income of -$5.4M. Notably, ARS Pharmaceuticals, Inc.'s price-to-earnings ratio is 174.21x while Vivos Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARS Pharmaceuticals, Inc. is 6.91x versus 0.77x for Vivos Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPRYARS Pharmaceuticals, Inc.6.91x 174.21x $32.5M -$51.2M VVOSVivos Therapeutics, Inc.0.77x -- $6.8M -$5.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
53
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 30x
Alerts
Sell
40
BILL alert for Feb 7
Bill Holdings, Inc. [BILL] is up 37.11% over the past day.
Buy
75
PRLB alert for Feb 7
Proto Labs, Inc. [PRLB] is up 28.33% over the past day.
Sell
30
MSTR alert for Feb 7
Strategy, Inc. [MSTR] is up 26.08% over the past day.
